Trial Profile
A prospective, open-label, multicenter study to evaluate the pharmacokinetic, efficacy, and safety of Nonacog-alfa in previously treated patients with moderately severe to severe haemophilia B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2016
Price :
$35
*
At a glance
- Drugs Nonacog alfa (Primary)
- Indications Haemophilia B
- Focus Pharmacokinetics
- Sponsors Pfizer
- 16 Mar 2016 New trial record
- 08 Mar 2016 Results published in the Clinical Therapeutics.